← Leaderboards
Eleni Tiniakou
Johns Hopkins University
$1,090,307
Attributed
$1,512,002
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $763K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,512,002 · 3
By mechanism
K08$793,645 · 1
R21$718,357 · 2
Top collaborators
- James Andrews2 shared
- Brendan Antiochos1 shared
- Jungsan Sohn1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Roberta W Scherer$8,044,136
- Paul B Rosenberg$14,116,062
- Ami Aalok Shah$3,647,591
- Michal L Melamed$11,008,976
- Hugo W Moser$5,176,943
Others in their field
Other Emerging Leaders on “Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$169,304,044
- Yunda Huang · Fred Hutchinson Cancer Center$73,421,550
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Hanjoon Ryu$28,519,898
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$27,369,420
Research focus
AntibodiesAutoantibodiesPathogenesisFutureMorbidity - Disease RateEpitopesFlow CytometryRheumatismT-LymphocyteImmunologyTherapeutic TargetImmunologicsFrequenciesMediatingAutoimmuneResourcesPlayCd4 Positive T LymphocytesImmunoglobulinsAffectRecording Of Previous EventsSpecificityLinkAntigens
Grant awards (8)
RNA: Polymerase III specific CD8+ T cells: a mechanistic insight into cancer-induced autoimmunity in scleroderma$158,729
K08 · FY2025 · AR · contact PI
The MIGHT Trial - An Exploratory Clinical Trial of IVIG in anti-HMGCR ImmuneMediated Necrotizing Myopathy$114,039
R21 · FY2025 · AR
Delineating the interplay between nucleic-acid-dependent phase separation and immune responses against cGAS in SLE$375,100
R21 · FY2024 · AR
The MIGHT Trial - An Exploratory Clinical Trial of IVIG in anti-HMGCR ImmuneMediated Necrotizing Myopathy$229,218
R21 · FY2024 · AR
RNA Polymerase III specific CD8+ T cells: a mechanistic insight into cancer-induced autoimmunity in scleroderma$158,729
K08 · FY2024 · AR · contact PI
RNA Polymerase III specific CD8+ T cells: a mechanistic insight into cancer-induced autoimmunity in scleroderma$158,729
K08 · FY2023 · AR · contact PI
RNA Polymerase III specific CD8+ T cells: a mechanistic insight into cancer-induced autoimmunity in scleroderma$158,729
K08 · FY2022 · AR · contact PI
RNA Polymerase III specific CD8+ T cells: a mechanistic insight into cancer-induced autoimmunity in scleroderma$158,729
K08 · FY2021 · AR · contact PI